Here is a fun fact about American healthcare that nobody puts on a billboard: an enormous share of it runs on software and clinical labor supplied by contractors most people have never heard of. When a state Medicaid agency pays a claim, when Medicare checks whether a hospital gave you decent care, when a provider clicks "submit" on a prior authorization and waits - a contractor is usually somewhere in that loop. Acentra Health is one of the larger such contractors. It is roughly a $700 million-a-year business, it employs around 3,300 people, and its entire commercial strategy is to be indispensable and invisible at the same time.

Acentra Health is new as a name and old as a business. It was formed in 2023 out of the merger of two companies: CNSI, a Medicaid systems company, and Kepro, a clinical-services and quality-oversight company. The merger closed in December 2022; the combined company spent the next six months picking a name that sounds like "accelerate" and "central" fused together, and in June 2023 announced that CNSI and Kepro were now Acentra Health. This is the corporate equivalent of two people getting married and hyphenating into a third surname that neither family had before.

The logic of the merger is the sort of thing that sounds obvious on a slide and is brutal in practice. CNSI wrote software - the big transactional systems that states use to process Medicaid claims. Kepro supplied clinicians - the nurses and reviewers who decide whether a service is medically necessary, whether an appeal has merit, whether a patient is in the right level of care. If you are a state government, you would prefer to buy those two things from one vendor rather than two, because integration is your problem otherwise. Acentra's pitch is that it is both the software and the people, sold together, so the state doesn't have to be the systems integrator. Whether that pitch survives contact with the reality of merging an engineering culture with a nursing culture is a genuinely hard question, and it is the central operational story of the company.

What does Acentra actually build? The two products worth knowing are evoBrix X and Atrezzo. evoBrix X is a modular Medicaid Enterprise System - the class of software that replaces the decades-old mainframes some states still use to run their Medicaid programs. The important word is "modular." The old way to modernize a Medicaid system was a terrifying multi-year, all-or-nothing rewrite, the kind of government IT project that occasionally becomes a newspaper scandal. The federal government (via CMS) now encourages states to buy modules - claims here, provider management there, pharmacy over there - and stitch them together, each certified separately. evoBrix X is Acentra's set of modules for that world. It is a bet that modernization can be incremental, which is a nicer thing to sell to a state that has watched a big-bang project fail before.

Atrezzo is the clinical side: an AI-enabled platform that unifies utilization management, care and case management, appeals, assessments, and eligibility, with a web portal where providers can watch an authorization request move through the pipeline in real time. If you have ever wondered where the great American ritual of prior authorization physically happens, some meaningful fraction of it happens in software like this. Acentra's entire product thesis on Atrezzo is that prior authorization - the most reliably hated process in all of American medicine - can be made faster and less opaque. That is a low bar and an enormous market, which is a good combination for a business.

The government-as-customer business

The thing to understand about Acentra is that its customer is almost always a government. State Medicaid agencies. The federal Centers for Medicare & Medicaid Services. Occasionally a commercial health organization, but the center of gravity is public-sector. This shapes everything. Government contracts are large, long, and slow to win, and once you have them they are extremely sticky, because switching vendors on a live Medicaid system is the kind of decision that ends careers. Acentra's $298 million CMS contract renewal to keep doing Medicare beneficiary quality work is a good illustration: the money is in the renewal, and the renewal is a function of having done the last one without a disaster.

Acentra serves as a Beneficiary and Family Centered Care-Quality Improvement Organization - a "BFCC-QIO," a phrase that exists to be an acronym - under CMS contract across roughly 29 states. In plain English: when a Medicare patient complains about the quality of their care, or disputes being discharged too early, an independent reviewer has to look at it. Acentra is one of the companies CMS pays to be that independent reviewer. It is not glamorous. It is deeply load-bearing.

Behind Acentra sits The Carlyle Group, the global private-equity firm. This is not incidental. Carlyle does not buy companies to make them famous; it buys them to compound - to grow revenue, win renewals, and eventually sell or take public at a higher multiple. A steady, mission-critical, government-contracted healthcare services business is exactly the kind of asset a PE firm likes: predictable, defended by switching costs, and unsexy enough that nobody bids it up on hype. Four consecutive years on the Washington Business Journal's largest-private-companies list, climbing 23 spots over four years, is what patient compounding looks like on a chart.

It is worth being clear about who Acentra competes with, because the names tell you what kind of business this is. On the systems side it lines up against companies like Gainwell Technologies, Conduent, and Maximus - the large integrators that states hire to run the machinery of public benefits. On the clinical-oversight side it competes with other utilization-management and quality-review vendors. None of these are consumer brands, and that is the point. The competition is for government contracts, evaluated by procurement officers reading hundred-page proposals, and won by whoever can credibly promise scale, compliance, and no surprises. It is a market where the boring answer usually wins, and Acentra has organized itself to be the boring answer.

Two continents, one delivery machine

Acentra is headquartered in McLean, Virginia, in the dense belt of government contractors that rings Washington, with more than 30 U.S. office locations and a substantial delivery center in Chennai, India. This is standard for the category - the engineering and back-office work spans two continents and time zones, while the client-facing clinical and account work stays close to the statehouses that write the checks. The company was named to the Northern Virginia Technology Council's Tech100 in December 2025, which is the regional tech establishment's way of saying: yes, this is one of ours.

Leadership traces back to the merger. Todd Stottlemyer, who ran CNSI, became CEO of the combined company; Susan Weaver, who ran Kepro, came in as President. Both sat on the board. That is the textbook structure for a merger-of-equals-that-is-never-quite-equal, and the interesting management question - the one you can't answer from a press release - is how cleanly two executive teams actually became one.

The culture the company describes for itself is exactly what you would expect from a mission-driven government contractor: "accelerating better outcomes," heavy on client collaboration, workforce investment, and the language of public service. Some of that is standard-issue corporate positioning. But a business built around Medicaid and Medicare does attract a particular kind of employee - people who are comfortable with the idea that the customer is a state agency, the end user is often someone on public benefits, and the work is measured in renewals rather than viral launches. The regional awards - fastest-growing lists, best-workplace nods, the Tech100 - are the visible scorecard for that, and Acentra has collected them at a steady clip.

What you can actually do with it

If you are a state health official, Acentra is a way to modernize a Medicaid system without betting your job on a single monolithic rewrite, and to outsource the clinical review work - authorizations, assessments, appeals - to people who do it at scale. If you are a provider, Acentra is more likely the portal you log into to get an authorization decided, and the thing you quietly hope will be fast. If you are a Medicare beneficiary, Acentra may be the independent party reviewing a complaint you'll never know you filed with a contractor. And if you are an investor or an operator studying the unglamorous middle of healthcare, Acentra is a clean example of the whole category: software plus clinicians plus government contracts plus private-equity patience.

The honest summary is that Acentra Health is not trying to delight you. It is trying to be the layer of technology and clinical labor that sits between hospitals, insurers, and the government - and to be reliable enough that the states renewing its contracts never have to think hard about whether to. That is a modest ambition stated plainly, and in a sector full of companies promising to reinvent healthcare, there is something clarifying about one that mostly promises to keep it running.